Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis

Trial Profile

Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs PRS 080 (Primary)
  • Indications Anaemia
  • Focus Adverse reactions
  • Sponsors Pieris Pharmaceuticals
  • Most Recent Events

    • 19 Oct 2017 Planned End Date changed from 1 Jun 2017 to 31 Dec 2017.
    • 09 Aug 2017 According to a Pieris Pharmaceuticals media release, the company has completed a Phase Ib single ascending dose study during the second quarter of 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top